Altretamine (hexamethylmelamine) platinum-resistant卵巢癌的治疗:一项II期研究。

文章的细节

引用

复制到剪贴板

Keldsen N, Havsteen H, Vergote我Bertelsen K, Jakobsen一个

Altretamine (hexamethylmelamine) platinum-resistant卵巢癌的治疗:一项II期研究。

88年2月Gynecol杂志。2003;(2):118 - 22所示。

PubMed ID

12586589 (在PubMed

]

文摘

目的:探讨口服Altretamine的活动在卵巢上皮癌的女性反应(公关或CR)第一行化疗,但在6个月内复发。协议后来修改包含在12个月内复发患者。方法:多中心II期试验。病人必须衡量疾病。不超过一个前化疗团是允许的。病人服用260毫克/ m(2) /天Altretamine为2周,分四次,重复每4周。后的反应是评估每两个课程。结果:31个符合条件的患者接受3门课程的平均Altretamine(范围1 - 12)。血液毒性最小。胃肠道毒性是常见的。 Response evaluation was possible for 26 patients. Three patients (9.7% intent-to-treat) achieved a partial response. Eight patients had stable disease, and 15 patients had progressive disease after two treatment courses. The median time to progression was 10 weeks (range, 5-51 weeks). Medial survival was 34 weeks (range, 7-112+). CONCLUSION: Altretamine should not be chosen as standard treatment in patients with platinum-resistant recurrent ovarian cancer. However, Altretamine represents a useful alternative in patients who prefer oral treatment or when socioeconomic considerations are an important issue.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

Altretamine